Skip to main content
Premium Trial:

Request an Annual Quote

People in the News: Paul Grint, Jennifer Doudna, Emmanuelle Charpentier

Premium

Regulus Therapeutics has appointed Paul Grint as its chief medical officer.

Grint joins the company from Cerexa, a subsidiary of Forest Laboratories, where he served as president and was responsible for the company's anti-infective product pipeline. Before that, he was senior vice president of research at Forest Research Institute.


Johnson & Johnson has announced that University of California, Berkeley's Jennifer Doudna and Hannover Medical School's Emmanuelle Charpentier have been named the winners of this year's Dr. Paul Janssen Award for Biomedical Research.

Doudna and Charpentier received the award for their groundbreaking research into CRISPR-Cas9, a bacterial immunity mechanism in which a short strand of RNA guides a nuclease to a specific area of DNA where it triggers double-strand breaks. The technology has since been refined and adopted by researchers for gene-editing applications.

The Scan

Purnell Choppin Dies

Purnell Choppin, a virologist who led the Howard Hughes Medical Institute, has died at 91, according to the Washington Post.

Effectiveness May Decline, Data From Israel Suggests

The New York Times reports that new Israeli data suggests a decline in Pfizer-BioNTech SARS-CoV-2 vaccine effectiveness against Delta variant infection, though protection against severe disease remains high.

To See Future Risk

Slate looks into the use of polygenic risk scores in embryo screening.

PLOS Papers on Methicillin-Resistant Staphylococcus, Bone Marrow Smear Sequencing, More

In PLOS this week: genomic analysis of methicillin-resistant Staphylococcus pseudintermedius, archived bone marrow sequencing, and more.